Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2020

06.08.2019 | Original Article

Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma

verfasst von: Pınar Cömert, Abdulkerim Yıldız, Murat Yıldırım, Hacer Berna Afacan Öztürk, Çiğdem Pala, Murat Albayrak, Meltem Aylı

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Low-grade Nonhodgkin lymphoma (LG-NHL) is characterized by indolent clinical course, which consist of marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, waldenstrom macroglobulinemia (WM) as the most common subtypes. Factors affecting prognosis and treatment need in these patients have long been the subject of research. A retrospective study was conducted with patients diagnosed with LG-NHL in Hematology Departments of two centres between 2010 and 2018. At the time of diagnosis, demographic and disease characteristics, hematological and biochemical parameters were examined. Using these data, treatment requirements, response and survival rates were calculated. The effect of parameters on survival and need to treatment were analyzed. 93 LG-NHL patients were included in this study. 40 (43%) of these patients were MZL, 28 (30.1%) were FL and 25 (26.8%) were others. In comparison of patients required treatment with patients without treatment, there was significant difference among the number of comorbidity, platelet count, neutrophil count, disease subgroups and ferritin levels. Logistic regression analysis revealed that disease subgroup (other than MZL and FL) and ferritin levels were independent risk factors for need to treatment. Only ferritin level was found to be associated with overall survival. The current study demonstrated an association between serum ferritin levels and prognosis in patients with LG-NHL. Given that it is easily available and low-cost, the initial ferritin level can be used as a prognostic marker for patients with indolent lymphoma.
Literatur
1.
Zurück zum Zitat Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRef Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRef
2.
Zurück zum Zitat Morin RD, Marra MA, Mungall AJ, Hirst M, Mendez-Lago M, Gascoyne RD et al. (2018) Biomarkers for non-hodgkin lymphomas and uses thereof. Google Patents Morin RD, Marra MA, Mungall AJ, Hirst M, Mendez-Lago M, Gascoyne RD et al. (2018) Biomarkers for non-hodgkin lymphomas and uses thereof. Google Patents
3.
Zurück zum Zitat Rosenberg S, Dorfman R, Kaplan H (1975) A summary of the results of a review of 405 patients with non-Hodgkin's lymphoma at Stanford University. Br J Cancer Suppl 2:168PubMedPubMedCentral Rosenberg S, Dorfman R, Kaplan H (1975) A summary of the results of a review of 405 patients with non-Hodgkin's lymphoma at Stanford University. Br J Cancer Suppl 2:168PubMedPubMedCentral
4.
Zurück zum Zitat Cabanillas F, Rivera N, Pardo WI (2016) Indolent Lymphomas that present with clinically aggressive features: a subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis. Clin Lymphoma Myeloma Leukemia. 16(10):550–557CrossRef Cabanillas F, Rivera N, Pardo WI (2016) Indolent Lymphomas that present with clinically aggressive features: a subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis. Clin Lymphoma Myeloma Leukemia. 16(10):550–557CrossRef
5.
Zurück zum Zitat Arcaini L, Rattotti S, Gotti M, Luminari S (2012) Prognostic assessment in patients with indolent B-cell lymphomas. Sci World J 2012: 107892 Arcaini L, Rattotti S, Gotti M, Luminari S (2012) Prognostic assessment in patients with indolent B-cell lymphomas. Sci World J 2012: 107892
6.
Zurück zum Zitat Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562CrossRef Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562CrossRef
7.
Zurück zum Zitat Wu CJ (2012) CLL clonal heterogeneity: an ecology of competing subpopulations. Blood 120(20):4117–4118CrossRef Wu CJ (2012) CLL clonal heterogeneity: an ecology of competing subpopulations. Blood 120(20):4117–4118CrossRef
8.
Zurück zum Zitat Federico M, Molica S, Bellei M, Luminari S (2009) Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malignancy Rep 4(4):202–210CrossRef Federico M, Molica S, Bellei M, Luminari S (2009) Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malignancy Rep 4(4):202–210CrossRef
9.
Zurück zum Zitat Sehn LH (2006) Optimal use of prognostic factors in non-Hodgkin lymphoma. ASH Educ Program Book 2006(1):295–302 Sehn LH (2006) Optimal use of prognostic factors in non-Hodgkin lymphoma. ASH Educ Program Book 2006(1):295–302
10.
Zurück zum Zitat Aulbert E, Fromm H, Hornemann H (1991) Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia. Medizinische Klinik (Munich, Germany: 1983) 86(6):297–304 Aulbert E, Fromm H, Hornemann H (1991) Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia. Medizinische Klinik (Munich, Germany: 1983) 86(6):297–304
11.
Zurück zum Zitat Matzner Y, Konijn A, Hershko C (1980) Serum ferritin in hematologic malignancies. Am J Hematol 9(1):13–22CrossRef Matzner Y, Konijn A, Hershko C (1980) Serum ferritin in hematologic malignancies. Am J Hematol 9(1):13–22CrossRef
12.
Zurück zum Zitat Ohnishi K, Shimizu K, Yamada H, Kunii A (1985) Quantification of ferritin-secreting cells in patients with non-Hodgkin’s lymphoma. Acta Haematol 73(3):145–149CrossRef Ohnishi K, Shimizu K, Yamada H, Kunii A (1985) Quantification of ferritin-secreting cells in patients with non-Hodgkin’s lymphoma. Acta Haematol 73(3):145–149CrossRef
13.
Zurück zum Zitat Kalousová M, Krechler T, Jáchymová M, Kuběna AA, Žák A, Zima T (2012) Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumor Biol 33(5):1695–1700CrossRef Kalousová M, Krechler T, Jáchymová M, Kuběna AA, Žák A, Zima T (2012) Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumor Biol 33(5):1695–1700CrossRef
14.
Zurück zum Zitat Alkhateeb AA, Connor JR (2013) The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta (BBA)-Rev Cancer. 1836(2):245–54 Alkhateeb AA, Connor JR (2013) The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta (BBA)-Rev Cancer. 1836(2):245–54
15.
Zurück zum Zitat Alkhateeb AA, Connor JR (2010) Nuclear ferritin: a new role for ferritin in cell biology. Biochim Biophys Acta (BBA)-Gen Sub 1800(8):793–7CrossRef Alkhateeb AA, Connor JR (2010) Nuclear ferritin: a new role for ferritin in cell biology. Biochim Biophys Acta (BBA)-Gen Sub 1800(8):793–7CrossRef
16.
Zurück zum Zitat Recalcati S, Invernizzi P, Arosio P, Cairo G (2008) New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 30(1–2):84–89CrossRef Recalcati S, Invernizzi P, Arosio P, Cairo G (2008) New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 30(1–2):84–89CrossRef
17.
Zurück zum Zitat Yoh KA, Lee HS, Park LC, Lee EM, Shin SH, Park DJ et al (2014) The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia 14(1):43–49CrossRef Yoh KA, Lee HS, Park LC, Lee EM, Shin SH, Park DJ et al (2014) The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leukemia 14(1):43–49CrossRef
18.
Zurück zum Zitat Dörner MH, Abel U, Fritze D, Manke HG, Drings P (1983) Serum ferritin in relation to the course of Hodgkin's disease. Cancer 52(12):2308–2312CrossRef Dörner MH, Abel U, Fritze D, Manke HG, Drings P (1983) Serum ferritin in relation to the course of Hodgkin's disease. Cancer 52(12):2308–2312CrossRef
19.
Zurück zum Zitat Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y et al (2017) Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol 39(1):112–117CrossRef Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y et al (2017) Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol 39(1):112–117CrossRef
20.
Zurück zum Zitat Zhang X-Z, Su A-L, Hu M-Q, Zhang X-Q, Xu Y-L (2014) Elevated serum ferritin levels in patients with hematologic malignancies. Asian Pac J Cancer Prev. 15(15):6099–6101CrossRef Zhang X-Z, Su A-L, Hu M-Q, Zhang X-Q, Xu Y-L (2014) Elevated serum ferritin levels in patients with hematologic malignancies. Asian Pac J Cancer Prev. 15(15):6099–6101CrossRef
Metadaten
Titel
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma
verfasst von
Pınar Cömert
Abdulkerim Yıldız
Murat Yıldırım
Hacer Berna Afacan Öztürk
Çiğdem Pala
Murat Albayrak
Meltem Aylı
Publikationsdatum
06.08.2019
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2020
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01168-9

Weitere Artikel der Ausgabe 1/2020

Indian Journal of Hematology and Blood Transfusion 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.